Scarica l'app Stockscreener
1.70
1.19%
0.02
Pre-mercato:
1.68
-0.02
-1.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.68
Aprire:
$1.72
Volume 24 ore:
361.45K
Relative Volume:
0.40
Capitalizzazione di mercato:
$184.08M
Reddito:
$27.08M
Utile/perdita netta:
$-37.00M
Rapporto P/E:
-3.2692
EPS:
-0.52
Flusso di cassa netto:
$-18.46M
1 W Prestazione:
+5.59%
1M Prestazione:
+4.29%
6M Prestazione:
-32.27%
1 anno Prestazione:
+25.93%
Intervallo 1D:
$1.665
$1.72
Intervallo di 1 settimana:
$1.61
$1.78
Portata 52W:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.70 | 181.91M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Piper Sandler | Overweight |
| 2025-05-28 | Iniziato | Wedbush | Outperform |
| 2025-03-18 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
What are analysts’ price targets for Aclaris Therapeutics Inc. in the next 12 monthsHarness the power of proven investment plans - jammulinksnews.com
What are the latest earnings results for Aclaris Therapeutics Inc.Capitalize on emerging growth stocks - jammulinksnews.com
How Resilient Is Aclaris Therapeutics Inc. Stock During Economic DownturnsLong Term Secure Gain Stocks - Newser
Published on: 2025-07-27 19:20:18 - jammulinksnews.com
How Efficient Is Aclaris Therapeutics Inc. at Controlling Operating CostsInsider Level Guidance - Newser
What drives Aclaris Therapeutics Inc. stock priceRapidly expanding wealth - PrintWeekIndia
Aclaris Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What institutions are buying Aclaris Therapeutics Inc. stock nowPhenomenal returns - jammulinksnews.com
What analysts say about Aclaris Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Why Aclaris Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - Newser
LENZ Therapeutics Inc. Stock Analysis and ForecastPhenomenal capital appreciation - Autocar Professional
Is Aclaris Therapeutics Inc. a good long term investmentRapid capital growth - jammulinksnews.com
How Aclaris Therapeutics Inc. stock performs during market volatilityDaily Volume Leaders - Newser
What makes Aclaris Therapeutics Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Insider Monkey
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
Piper Sandler Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics' Recent Gains Improve Losses On Insider Purchases Worth US$1.50m - simplywall.st
Plus Therapeutics (NASDAQ:PSTV) vs. Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey - Defense World
Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Aclaris Therapeutics at HCW Conference: Strategic Moves and Future Plans By Investing.com - Investing.com Canada
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes - Investing.com
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Aclaris Added to Russell Indexes: $10.6T in Benchmark Assets Now Track Biotech Stock - Stock Titan
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Completeness Index - MarketScreener
Aclaris Therapeutics joins Russell 3000 and Russell 2000 indexes By Investing.com - Investing.com UK
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):